Novoseven, Novoseven RT Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising diagnosis of rare bleeding disorders, increased use of bypassing agents in hemophilia care, expansion of specialized hematology centers, improved access to recombinant therapies, growing clinical acceptance of rFVIIa products.

The growth in the forecast period can be attributed to increasing focus on personalized bleeding disorder management, rising demand for rapid-acting clotting agents, expansion of global access programs, advancements in recombinant drug manufacturing, growing adoption in emergency bleeding scenarios. Major trends in the forecast period include increasing use of recombinant coagulation therapies, growing adoption in surgical bleeding management, expansion of indications for rare bleeding disorders, enhanced focus on rapid hemostasis solutions, improved cold-chain distribution practices.

The growing prevalence of hemophilia is expected to drive the growth of the NovoSeven and NovoSeven RT market going forward. Hemophilia is a rare genetic bleeding disorder caused by a deficiency or absence of specific clotting factors, impairing the body’s ability to form proper blood clots and leading to prolonged or spontaneous bleeding, particularly after injuries or surgeries. The prevalence of hemophilia is rising due to improved diagnosis, better disease management increasing life expectancy, and population growth. NovoSeven and NovoSeven RT provide recombinant activated factor VII therapy, effectively controlling and preventing bleeding episodes in patients, especially those with inhibitors to standard clotting factor therapies, ensuring better management of this genetic disorder. For instance, in April 2025, Hemophilia News Today reported that the global prevalence of hemophilia is estimated at approximately 836,000 people worldwide. Therefore, the growing prevalence of hemophilia is driving the growth of the NovoSeven and NovoSeven RT market.

The rising number of complex surgical procedures is expected to propel the growth of the NovoSeven and NovoSeven RT market going forward. Complex surgical procedures involve high-risk operations with multiple steps or specialized techniques to treat severe or complicated medical conditions. The increase in such procedures is largely driven by the growing prevalence of chronic diseases and advanced medical conditions requiring intricate interventions. NovoSeven and NovoSeven RT support these procedures by effectively controlling bleeding in patients with hemophilia or acquired coagulation deficiencies. For instance, in November 2024, the Private Healthcare Information Network (PHIN) reported that in Q1 2024, 22,700 robot-assisted procedures were performed in the UK, marking a 45% increase from Q1 2023 and a 12% rise from Q4 2023. Therefore, the rising number of complex surgical procedures is driving the growth of the NovoSeven and NovoSeven RT market.

The increasing healthcare expenditure is expected to propel the growth of the NovoSeven and NovoSeven RT market going forward. Healthcare expenditure includes the total spending by individuals, governments, or organizations on medical goods, services, public health initiatives, and research activities to maintain and improve health. Rising healthcare expenditure is driven by aging populations, increasing chronic disease prevalence, and the need for better healthcare infrastructure. NovoSeven and NovoSeven RT contribute by providing effective treatments for severe bleeding conditions, such as hemophilia and postpartum hemorrhage, potentially reducing the need for costly emergency interventions, prolonged hospital stays, and additional procedures, thereby improving cost-efficiency in healthcare management. For instance, in June 2024, Health Affairs reported that U.S. healthcare spending is projected to grow from 17.3% of GDP in 2022 to 19.7% by 2032, with a 7.5% increase in national health expenditures estimated for 2023. Therefore, increasing healthcare expenditure is driving the growth of the NovoSeven and NovoSeven RT market.

Major companies operating in the novoseven, novoseven rt market are Novo Nordisk A/S.

North America was the largest region in the novoseven, novoseven RT market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novoseven, novoseven rt market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the novoseven, novoseven rt market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the novoseven and novoseven RT market by increasing costs associated with imported biopharmaceutical raw materials, single-use manufacturing components, cold-chain logistics systems, and specialized packaging materials. North America and Europe are most affected due to dependence on cross-border biologics supply chains, while emerging markets face higher procurement costs through imports. These tariffs contribute to elevated treatment costs and pricing pressure on healthcare systems. However, they are also encouraging localized biologics manufacturing, regional fill-finish investments, and strengthened domestic supply resilience for critical bleeding disorder therapies.

The novoseven, novoseven rt market research report is one of a series of new reports that provides novoseven, novoseven rt market statistics, including novoseven, novoseven rt industry global market size, regional shares, competitors with a novoseven, novoseven rt market share, detailed novoseven, novoseven rt market segments, market trends and opportunities, and any further data you may need to thrive in the novoseven, novoseven rt industry. This novoseven, novoseven rt market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Novoseven and Novoseven RT are recombinant activated factor VII (rFVIIa) therapies designed to support blood clotting in patients with specific bleeding disorders, including hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann’s thrombasthenia. They are primarily used to control bleeding episodes and during surgical or invasive procedures in these patients.

The main indications for Novoseven and Novoseven RT are hemophilia A, hemophilia B, and other rare bleeding disorders. Hemophilia A is a genetic condition caused by a deficiency or dysfunction of clotting factor VIII, resulting in prolonged bleeding episodes that require ongoing management to prevent spontaneous or severe bleeding, which can be life-threatening. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used by adult, pediatric, and geriatric patients.

The novoseven, novoseven RT market consists of sales of recombinant factor viii, activated prothrombin complex concentrates, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.